| Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Advancing drug development in myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Consensus recommendations for severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
|
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
